Genmab (OTCPK:GNMS.F) - Stock Price, News & Analysis

Resumen acción GNMS.F

Genmab A/S desarrolla terapias de anticuerpos para el tratamiento del cáncer y otras enfermedades, principalmente en Dinamarca.

Acerca de la empresa

GNMS.F fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	4/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Recompensas

Cotiza un 48.7% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 24.56%

Análisis de riesgos

GNMS.F ha superado nuestros controles de riesgos.

Competidores de Genmab A/S

Horizon Therapeutics

NasdaqGS:HZNP

US$26.6b

Neurocrine Biosciences

NasdaqGS:NBIX

US$13.8b

BioMarin Pharmaceutical

NasdaqGS:BMRN

US$16.9b

BioNTech

NasdaqGS:BNTX

US$21.7b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Genmab
Historical stock prices
Current Share Price	kr.297.74
52 Week High	kr.432.30
52 Week Low	kr.262.00
Beta	0.78
1 Month Change	-4.75%
3 Month Change	-4.91%
1 Year Change	-24.45%
3 Year Change	-15.77%
5 Year Change	73.23%
Change since IPO	1,741.31%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	GNMS.F	US Biotechs	Mercado US
7D	1.9%	-1.7%	0.3%
1Y	-24.5%	4.7%	26.2%

Rentabilidad frente al sector: GNMS.F obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del 4.4%.

Rentabilidad vs. Mercado: GNMS.F obtuvo unos resultados inferiores a los del mercado US, que fue del 20.5% el año pasado.

Volatilidad de los precios

Is GNMS.F's price volatile compared to industry and market?
GNMS.F volatility
GNMS.F Average Weekly Movement	4.8%
Biotechs Industry Average Movement	11.8%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: GNMS.F no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de GNMS.F (6%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1999	2,204	Jan G.J. van Winkel	https://www.genmab.com

Genmab A/S desarrolla anticuerpos terapéuticos para el tratamiento del cáncer y otras enfermedades, principalmente en Dinamarca. La empresa comercializa DARZALEX, un anticuerpo monoclonal humano para el tratamiento de pacientes con mieloma múltiple (MM); teprotumumab para el tratamiento de la enfermedad ocular tiroidea; y Amivantamab para el cáncer gástrico o esofágico avanzado o metastásico y el CPNM. Sus productos incluyen daratumumab para tratar MM, cánceres de la sangre no MM y amiloidosis AL; GEN1047; tisotumab vedotin para tratar cánceres de cuello uterino, ovario y sólidos; DuoBody-PD-L1x4-1BB, y DuoBody-CD40x4-1BB para tratar tumores sólidos; Epcoritamab para el linfoma difuso de células B grandes y la leucemia linfocítica crónica en recaída o refractarios; y HexaBody-CD38 y GEN3017 para el tratamiento de neoplasias hematológicas.

Resumen de fundamentos de Genmab A/S

¿Cómo se comparan los beneficios e ingresos de Genmab con su capitalización de mercado?
Estadísticas fundamentales de GNMS.F
Capitalización bursátil	US$19.55b
Beneficios(TTM)	US$626.79m
Ingresos (TTM)	US$2.37b

31.2x

Ratio precio-beneficio (PE)

8.2x

Ratio precio-ventas (PS)

¿Está GNMS.F sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de GNMS.F
Ingresos	kr.16.47b
Coste de los ingresos	kr.226.00m
Beneficio bruto	kr.16.25b
Otros gastos	kr.11.90b
Beneficios	kr.4.35b

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

May 02, 2024

Beneficios por acción (BPA)	66.88
Margen bruto	98.63%
Margen de beneficio neto	26.42%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado GNMS.F a largo plazo?

Ver rendimiento histórico y comparativa

Resumen acción GNMS.F

Recompensas

Análisis de riesgos

Competidores de Genmab A/S

NasdaqGS:HZNP

US$26.6b

NasdaqGS:NBIX

US$13.8b

NasdaqGS:BMRN

US$16.9b

NasdaqGS:BNTX

US$21.7b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Recent updates

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Genmab A/S Revises Earnings Guidance for 2022

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Genmab A/S Provides Earnings Guidance for the Year 2022

Genmab A/S Provides Earnings Guidance for the Year 2022

Genmab A/S Announces Janssen Received Conditional European Marketing Authorization for RYBREVANT

U.S. Food and Drug Administration Grants Approval to TIVDAK

Seagen Inc. and Genmab A/S Announce FDA Accelerated Approval for TIVDAK™ (Tisotumab Vedotin-Tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer

Genmab A/S Announces the Lancet Published the Results of FIH Trial

Genmab A/S Improves Revenue Guidance for the Full Year of Fiscal 2021

Genmab A/S Announces That Janssen Has Received European Marketing Authorizations for Darzalex® (Daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-Chain (Al) Amyloidosis

Genmab Announces Janssen Received Positive CHMP Opinion Recommending DARZALEX (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis

Genmab Announces Abstracts Evaluating Products in Pipeline, Portfolio to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

Genmab A/S Reaffirms Financial Guidance for Fiscal 2021

Genmab A/S Provides Revenue Guidance for the Full Year of Fiscal 2021

Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines

Seagen Inc. and Genmab A/S Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer

CHMP Issues Positive Opinion Recommending Genmab Ofatumumab in Relapsing Multiple Sclerosis

Genmab A/S to Report Fiscal Year 2020 Results on Feb 23, 2021

Genmab Announces That Janssen Has Been Granted U.S. FDA Approval for DARZALEX FASPRO® (Daratumumab and Hyaluronidase-Fihj) for Patients with Newly Diagnosed Light-Chain (AL) Amyloidosis

Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie

Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

Genmab A/S Announces Enapotamab Vedotin Update

ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease

Genmab A/S to Report Nine Months, 2021 Results on Nov 03, 2021